[Respiratory syncytial virus infection in childhood]

Area of Science:

• Pediatrics
• Infectious Diseases
• Pulmonology

Context:

• Respiratory syncytial virus (RSV) is a leading cause of infant respiratory tract infections and annual winter bronchiolitis epidemics.
• Despite extensive research, medical therapies for RSV bronchiolitis have seen limited advancements and remain controversial.
• Supportive care is crucial, with bronchodilators often ineffective and steroids/ribavirin generally not indicated for healthy infants.

Purpose:

• To review current treatment strategies for acute RSV bronchiolitis in infants.
• To evaluate the efficacy and indications for various medical interventions, including bronchodilators, steroids, and ribavirin.
• To discuss supportive care, potential benefits for high-risk groups, and future directions like consensus statements.

Summary:

• Inhaled bronchodilators lack consistent efficacy and should be used judiciously.
• Steroids and ribavirin are typically not recommended for otherwise healthy infants with RSV bronchiolitis, though specific risk groups may benefit.
• Supportive care is the cornerstone of management, leading to low mortality rates. Post-infectious lung function changes are usually temporary.

Impact:

• Current management emphasizes supportive care, recognizing that most infants recover fully with transient lung function alterations.
• While RSV immune globulins can protect high-risk infants, their use is limited by cost, side effects, and the generally benign nature of the disease.
• An international consensus statement is needed to standardize clinical practice and improve the management of RSV bronchiolitis.